

transforming some or all of the cells in an initial population of cells with a heterologous nucleotide sequence to form the population of cells containing one or more genetically transformed cells; wherein the heterologous nucleotide sequence is a first expressible nucleotide sequence encoding a first expression product wherein the expression product is an enzyme capable of metabolising galactose, a derivative of galactose, a precursor of galactose; and selecting at least one of the genetically transformed cells using the method of claim 25.

72. The method according to claim 71, wherein the genetically transformed cells further comprise a second expressible nucleotide sequence encoding a second expression product.

73. The method according to claim 72, wherein the genetically transformed cells further comprise a third expressible nucleotide sequence encoding a third expression product.

REMARKS

The above preliminary amendment is made merely to conform the claim structure to U. S. practice. A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Dr. Denise Kettelberger (Reg. No. 33,924), at 612.371.5268.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: February 9, 2001

By



John J. Gresens
Reg. No. 33,112

JJG/kas